Overall rank 51 · Score 106 · 2025 Nov 1
Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary Analysis.
Diabetes care
Randomized trialAI-recommended Tier AKidney
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 52 · Score 106 · 2025 Sep 18
Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.
The New England journal of medicine
Randomized trialAI-recommended Tier AWeight loss & obesity
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 53 · Score 106 · 2025 Nov 8
Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial.
Lancet (London, England)
Randomized trialAI-recommended Tier ACardiovascular
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 54 · Score 106 · 2025 Nov
Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme.
European journal of heart failure
Randomized trialAI-recommended Tier AHeart failure
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 55 · Score 105 · 2024 Jul
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial.
Nature medicine
Randomized trialAI-recommended Tier AWeight loss & obesityCardiovascularSafetyDiscontinuation & regain
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 56 · Score 105 · 2024 Jul 11
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
The New England journal of medicine
Randomized trialAI-recommended Tier ACardiovascularKidneyHeart failureSafety
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 57 · Score 105 · 2024 Aug 1
Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial.
Diabetes care
Randomized trialAI-recommended Tier AType 2 diabetesCardiovascularHeart failurePediatric & adolescent
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 58 · Score 105 · 2024 Sep 7
Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.
Lancet (London, England)
Randomized trialAI-recommended Tier ACardiovascularKidneyHeart failureSafety
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 59 · Score 105 · 2024 Aug 1
Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT.
Diabetes care
Randomized trialAI-recommended Tier AType 2 diabetesCardiovascularHeart failure
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 60 · Score 105 · 2024 Sep
Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial.
The lancet. Diabetes & endocrinology
Randomized trialAI-recommended Tier AWeight loss & obesitySafetyDiscontinuation & regain
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 61 · Score 105 · 2024 Oct 31
Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.
The New England journal of medicine
Randomized trialAI-recommended Tier AWeight loss & obesitySafetyDiscontinuation & regain
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 62 · Score 105 · 2024 Apr 27
Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials.
Lancet (London, England)
Randomized trialAI-recommended Tier ACardiovascularHeart failure
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 63 · Score 105 · 2024 Jul
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial.
Nature medicine
Randomized trialAI-recommended Tier ACardiovascularKidney
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 64 · Score 105 · 2024 Jul 2
Semaglutide and NT-proBNP in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program.
Journal of the American College of Cardiology
Randomized trialAI-recommended Tier ACardiovascularHeart failure
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 65 · Score 105 · 2024 Jul 16
Semaglutide and NYHA Functional Class in Obesity-Related Heart Failure With Preserved Ejection Fraction: The STEP-HFpEF Program.
Journal of the American College of Cardiology
Randomized trialAI-recommended Tier ACardiovascularHeart failure
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 66 · Score 105 · 2024 Sep
Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trial.
Diabetologia
Randomized trialAI-recommended Tier AType 2 diabetesDiscontinuation & regain
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 67 · Score 105 · 2024 Sep
Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, Phase IIIa, randomised trial.
Diabetologia
Randomized trialAI-recommended Tier AType 2 diabetesDiscontinuation & regain
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 68 · Score 105 · 2024 Aug
Metabolic effects of very-low calorie diet, Semaglutide, or combination of the two, in individuals with type 2 diabetes mellitus.
Clinical nutrition (Edinburgh, Scotland)
Randomized trialAI-recommended Tier AType 2 diabetesPediatric & adolescent
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 69 · Score 105 · 2024 Aug 24
Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.
Lancet (London, England)
Randomized trialAI-recommended Tier ACardiovascularHeart failure
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 70 · Score 105 · 2024 Oct 22
Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial.
Journal of the American College of Cardiology
Randomized trialAI-recommended Tier AKidneyHeart failure
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 71 · Score 105 · 2024 Oct 22
Inflammation in Obesity-Related HFpEF: The STEP-HFpEF Program.
Journal of the American College of Cardiology
Randomized trialAI-recommended Tier ACardiovascularHeart failure
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 72 · Score 105 · 2024 Oct 22
Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Program.
Journal of the American College of Cardiology
Randomized trialAI-recommended Tier ACardiovascularHeart failure
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 73 · Score 105 · 2024 Oct 22
Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure.
Journal of the American College of Cardiology
Randomized trialAI-recommended Tier ACardiovascularHeart failure
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 74 · Score 105 · 2024 Jan
Albuminuria-lowering effect of adding semaglutide on top of empagliflozin in individuals with type 2 diabetes: A randomized and placebo-controlled study.
Diabetes, obesity & metabolism
Randomized trialAI-recommended Tier AType 2 diabetes
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 75 · Score 105 · 2024 May
Separate and combined effects of empagliflozin and semaglutide on vascular function: A 32-week randomized trial.
Diabetes, obesity & metabolism
Randomized trialAI-recommended Tier AKidney
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Source registry generated 2026-09-17; AI appraisal completed 2026-09-22 under WPF-SGLT-AI-APPRAISAL-1.0. Humans resolve only the three displayed exceptions and record one accountable bundle publication decision. Records can appear in multiple domains; domain totals therefore overlap.